cro.directory
← Compare landing

TATAA Biocenter vs uBriGene

Side-by-side profile data from each company listing. Missing fields stay blank rather than filled with assumptions.

CategoryTATAA BiocenteruBriGene
SummaryGLP- and GCLP-compliant molecular CRO specializing in bioanalysis for gene therapy, RNA therapeutics, and advanced modalities, offering qPCR, NGS, and plasma proteomics services since 2001.uBriGene is a global leader in advanced therapy medicinal products (ATMPs), cell and gene therapy CDMO services, and analytical testing.
Services
  • Bioanalysis
  • Biomarker Assays
  • Translational Research
  • Genomics & Sequencing Services
  • Proteomics Services
  • US FDA Regulatory Strategy
  • EU EMA Regulatory Strategy
  • China NMPA Regulatory Strategy
  • Analytical Method Development & Validation
  • Translational Research
Modalities
  • Oligonucleotide
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • mRNA
  • Cell Therapy
  • Gene Therapy
  • AAV / Viral Vector Platform
IndicationsData not yet provided.
  • Oncology
Phases
  • Preclinical (General)
  • Phase I
  • Phase II
  • Phase III
  • Discovery
  • Preclinical (General)
  • Preclinical (IND-Enabling)
Sourcing models
  • Full-Service Outsourcing (FSO)
  • Full-Service Outsourcing (FSO)
Locations
  • Headquarters, Gothenburg, Västra Götaland, Sweden
  • Headquarters, Maryland, Maryland, USA
  • Boston, Boston, Massachusetts, USA
  • Worcester, Worcester, Massachusetts, USA
Certifications
  • SWEDAC · Identifier: GLP-accredited for qPCR, dPCR, and molecular biology
  • ISO/IEC · Identifier: ISO/IEC 17025-compliant
  • FDA · Identifier: 20+ INDs filed and accepted
  • EMA · Identifier: 20+ INDs filed and accepted
  • NMPA · Identifier: 20+ INDs filed and accepted

Find similar companies

TATAA Biocenter alternatives · uBriGene alternatives

Markdown mirror: /compare/tataa-biocenter/ubrigene.md